Lucent Technologies Inc.

Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

Other

Poche Palo Alto LLC

F. Hoffmann-la Roche Ag

James Patrick Dunn

David Michael Goldstein

Zachary Kevin Sweeney

Jian Jeffrey Chen

Christoph Martin Stahl

Tania M Silva

Peter H Nelson

Joan Heather Hogg

Julie Anne Lim

Teresa Alejandra Trejo-Martin

Eric Brian Sjogren

Dimitrios Stefanidis

Karl G Untch

Todd Richard Elworthy

Humberto Bartolome Arzeno

Bohdan Lew Bodnar

Donald Roy Hirschfeld

Mark Alan Lassig

Charles Calvin Byers

David Bernard Smith

Carl Robert Posthuma

Leyi Gong

Ronald Bruce Martin

Wylie Solang Palmer

David John Morgans, Jr

Achyutharao Sidduri

Alam Jahangir

Denis John Kertesz

Lawrence Emerson Fisher

Steven Swallow

Xiaochun Han

Stefan H Unger

Christophe Michoud

Eugene J Rosenthal

Bryan Russell Davies

Harit Vora

Dorothy V Stanley

Taraneh Mirzadegan

Conrad Martin Herse

Enn Tammaru

William Brohmer Paulson

Ian Edward David Smith

Parcharee Tivitmahaisoon

Teresa Rosanne Welch

William Harris

Don Howard Dvorak

John William Peterson

Thomas R Thieme

Shao-Yong Wu

Ronald David Slusky

Hsien-Chuen Yu

Brian William Dymock

Francisco X Talamas

Peng Zhang

Lubica Raptova

Donald Edward Crowe

Hoo-Yin Khoe

Deborah Carol Reuter

Daniel N Utberg

Kimerie Walzer Javitt

Jim W Barnett

Aaron Bayne Miller

Jack Kozik

Jack Ray Penrod

Deborah Margaret Stockert

Joan Marie Richied

Darin A Allen

Chakk S Ramesha

C Elliott Sigal

Christopher Huw Hill

Cecil Bernard Cates

Robert Petrelli

David L Ekstrom

Tania Silva

Compounds of formula I modulate JNK: wherein the variables are as defined herein.

JNK modulators

The present invention provides compositions for treating an HIV infection comprising administering a compound according to formula I where Ar, R-R, Rand Xare as defined herein with at least one carrier, excipient or diluent. 

Methods for treating retroviral infections

The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R, R, R, R, R, are as defined herein. 

Heterocyclic antiviral compounds

The invention relates to prodrugs of JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses prodrugs of JNK inhibitors, as described below in formula I: wherein m, n, p, q, Q, r, R, R, R, X, X, X, X, X, X, Y, Y, Zand Zare as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Inhibitors of JNK

The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficiency virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficiency virus containing a compound according to formula I where R, R, R, R, R, are as defined herein. 

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R-R, Rand Xare as defined herein. 

Compounds having the formula (I), are useful as p38 kinase inhibitors, wherein Rand Rare hydrogen, halogen, cyano, haloalkyl, or haloalkoxy, but are not both hydrogen; Rand Rare optional substituents, and Q is a non-aromatic moiety as defined in the specification.

Substituted quinazoline compounds useful as p38 kinase inhibitors

The present invention provides compounds of the Formula I and II: wherein R, R, W, Z, X, X, Ar, Rand Rare as defined herein, and methods and intermediates for their preparation and uses thereof.

6-Substituted pyrido-pyrimidines

This invention relates to methods of treating an HIV infection with novel heterocyclic compounds of formula I wherein R&#x2014;R, Xand Xare as defined in the summary and pharmaceutically acceptable salts, and methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I. 

Nonnucleoside reverse transcriptase inhibitors

The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R, R, R, R, R, R, Rand Rare as defined herein 

Non-nucleoside reverse transcriptase inhibitors

This invention relates to novel pyrazole derivatives of formula I wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I and pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 

This invention relates to novel heterocyclic compounds of formula I wherein R&#x2014;R, Xand Xare as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 

This invention relates to novel pyridazinone derivatives of formula I wherein R&#x2013;R, R, Rand Xare as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 

6-substituted pyrido-pyrimidines

Growing community of inventors

Los Altos, CA, United States of America

James Patrick Dunn